Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.
Martin-Orozco N, Vale N, Mihic A, Amor T, Reiter L, Arita Y, Samson R, Hu Q, Gingras AC, Sorenson BT, Marcusson EG, Patel P.
Martin-Orozco N, et al.
Sci Rep. 2023 May 26;13(1):8557. doi: 10.1038/s41598-023-35662-y.
Sci Rep. 2023.
PMID: 37236995
Free PMC article.
Clinical Trial.
The 40-g dose showed fewer adverse reactions than the 100-g dose, and therefore was selected for a Phase 2 trial, which is currently ongoing.Clinical Trial Registration number: NCT04765436 (21/02/2021). ( https://clinicaltrials.gov/ct2/show/NCT04765436 )....
The 40-g dose showed fewer adverse reactions than the 100-g dose, and therefore was selected for a Phase 2 trial, which is currently ongoing …